ABOUT US

meet us at
Oct. 25th - 27th - 2011
CPHI Frankfurt - Germany
March 12th - 15th - 2012
DCAT New York - USA

LAST NEWS
2011 - Certificate of GMP compliance of a Manufacturer for Human investigational medicinal product

2011 - Certificate of GMP compliance of a Manufacturer for Human medicinal product

MAA CESSION & TRANSFER
Licensing-out opportunity Cetirizine 10 mg/ml, oral solution (NL33352)
NEW MAA CESSION & TRANSFER
Licensing-out opportunity Donepezil 5 mg, ODT (NL37771) and Donepezil 10 mg, ODT (NL37772)
2009 - cGMP Agreement for human use

Galenix Pharma has obtained an updated agreement for cGMP manufacturing, importation and ditribution of human and investigational medicinal products AFSSAPS #M09/168
2008 - cGMP Agreement for veterinary use

Galenix Pharma has obtained an agreement for cGMP manufacturing, importation and distribution of veterinary and investigational medicinal products AFSSA #V1515/08
MAA CESSION & TRANSFER
Licensing-out opportunity Fenofibrate 67 mg, tablet (NL27271) - Fenofibrate 200 mg, tablet (NL27274) and Fenofibrate 160 mg, modified release tablet (NL31360)

newsletter signup
Subscribe Newsletter Please insert your email adress


indentification user
Forgot password Register

Galenix was founded in 1993 by its CEO, Mr Jerome Besse. The company is now ranked in the top European leaders for Pharmaceutical R&D and Drug Delivery Systems.

Galenix is your ideal strategic partner for outsourcing pharmaceutical development and innovative drug product acquisitions, with a full range of services for each stage of pharmaceutical Development process from preformulation, analytical and formulation development through clinical trial supplies for Phase I, II and III to scale-up and high volume pilot production.

This offer is customisable depending on the needs and the requirements of the clients.
Home - About us - Pharmaceutical Services - Clinical Supplies - Drug delivery - Business Opportunities - News - Job offers - Contact
Copyright © 2010 Galenix - Tous droits réservés